These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 36751044)
41. Clinical Outcomes and Response Predictors of Vedolizumab Induction Treatment for Korean Patients With Inflammatory Bowel Diseases Who Failed Anti-TNF Therapy: A KASID Prospective Multicenter Cohort Study. Kim J; Yoon H; Kim N; Lee KM; Jung SA; Choi CH; Kim ES; Jung Y; Eun CS; Kim TO; Kang SB; Kim YS; Seo GS; Lee CK; Im JP; Park SJ; Park DI; Ye BD Inflamm Bowel Dis; 2021 Nov; 27(12):1931-1941. PubMed ID: 33501935 [TBL] [Abstract][Full Text] [Related]
42. Aminosalicylates for induction of remission or response in Crohn's disease. Lim WC; Wang Y; MacDonald JK; Hanauer S Cochrane Database Syst Rev; 2016 Jul; 7(7):CD008870. PubMed ID: 27372735 [TBL] [Abstract][Full Text] [Related]
43. The impact of ustekinumab on extraintestinal manifestations of Crohn's disease: A post hoc analysis of the UNITI studies. Narula N; Aruljothy A; Wong ECL; Homenauth R; Alshahrani AA; Marshall JK; Reinisch W United European Gastroenterol J; 2021 Jun; 9(5):581-589. PubMed ID: 34077627 [TBL] [Abstract][Full Text] [Related]
45. Adalimumab for induction of remission in Crohn's disease. Abbass M; Cepek J; Parker CE; Nguyen TM; MacDonald JK; Feagan BG; Khanna R; Jairath V Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31742665 [TBL] [Abstract][Full Text] [Related]
46. Ustekinumab Serum Trough Levels May Identify Suboptimal Responders to Ustekinumab in Crohn's Disease. Painchart C; Brabant S; Duveau N; Nachury M; Desreumaux P; Branche J; Gérard R; Prevost CLD; Wils P; Lambin T; Boualit M; Labalette M; Pariente B Dig Dis Sci; 2020 May; 65(5):1445-1452. PubMed ID: 31599389 [TBL] [Abstract][Full Text] [Related]
47. Concomitant use of an immunomodulator with ustekinumab as an induction therapy for Crohn's disease: A systematic review and meta-analysis. Yoshihara T; Shinzaki S; Amano T; Iijima H; Takehara T; Inoue N; Uchino M; Esaki M; Kobayashi T; Saruta M; Sugimoto K; Nakamura S; Hata K; Hirai F; Hiraoka S; Fujii T; Matsuura M; Matsuoka K; Watanabe K; Nakase H; Watanabe M J Gastroenterol Hepatol; 2021 Jul; 36(7):1744-1753. PubMed ID: 33450096 [TBL] [Abstract][Full Text] [Related]
48. Certolizumab pegol for induction of remission in Crohn's disease. Yamazaki H; So R; Matsuoka K; Kobayashi T; Shinzaki S; Matsuura M; Okabayashi S; Kataoka Y; Tsujimoto Y; Furukawa TA; Watanabe N Cochrane Database Syst Rev; 2019 Aug; 8(8):CD012893. PubMed ID: 31476018 [TBL] [Abstract][Full Text] [Related]
49. Evaluation of ustekinumab trough levels during induction and maintenance therapy with regard to disease activity status in difficult to treat Crohn disease patients. Mechie NC; Burmester M; Mavropoulou E; Pilavakis Y; Kunsch S; Ellenrieder V; Amanzada A Medicine (Baltimore); 2021 Mar; 100(11):e25111. PubMed ID: 33725990 [TBL] [Abstract][Full Text] [Related]
50. A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn's disease refractory to biologic therapy. Forbes GM; Sturm MJ; Leong RW; Sparrow MP; Segarajasingam D; Cummins AG; Phillips M; Herrmann RP Clin Gastroenterol Hepatol; 2014 Jan; 12(1):64-71. PubMed ID: 23872668 [TBL] [Abstract][Full Text] [Related]
51. Ustekinumab is associated with superior treatment persistence but not with higher remission rates Bacsur P; Matuz M; Resál T; Miheller P; Szamosi T; Schäfer E; Sarlós P; Iliás Á; Szántó K; Rutka M; Bálint A; Milassin Á; Fábián A; Bor R; Szepes Z; Molnár T; Farkas K Therap Adv Gastroenterol; 2022; 15():17562848221144349. PubMed ID: 36600684 [TBL] [Abstract][Full Text] [Related]
52. Antibiotics for induction and maintenance of remission in Crohn's disease. Townsend CM; Parker CE; MacDonald JK; Nguyen TM; Jairath V; Feagan BG; Khanna R Cochrane Database Syst Rev; 2019 Feb; 2(2):CD012730. PubMed ID: 30731030 [TBL] [Abstract][Full Text] [Related]
53. Effectiveness and safety of Ustekinumab for Crohn's disease; systematic review and pooled analysis of real-world evidence. Engel T; Yung DE; Ma C; Pariente B; WIls P; Eliakim R; Ungar B; Ben-Horin S; Kopylov U Dig Liver Dis; 2019 Sep; 51(9):1232-1240. PubMed ID: 31202609 [TBL] [Abstract][Full Text] [Related]
54. Association between Ustekinumab Trough Levels, Serum IL-22, and Oncostatin M Levels and Clinical and Biochemical Outcomes in Patients with Crohn's Disease. Bertin L; Barberio B; Gubbiotti A; Bertani L; Costa F; Ceccarelli L; Visaggi P; Bodini G; Pasta A; Sablich R; Urbano MT; Ferronato A; Buda A; De Bona M; Del Corso G; Massano A; Angriman I; Scarpa M; Zingone F; Savarino EV J Clin Med; 2024 Mar; 13(6):. PubMed ID: 38541765 [No Abstract] [Full Text] [Related]
55. Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. Ferrante M; Panaccione R; Baert F; Bossuyt P; Colombel JF; Danese S; Dubinsky M; Feagan BG; Hisamatsu T; Lim A; Lindsay JO; Loftus EV; Panés J; Peyrin-Biroulet L; Ran Z; Rubin DT; Sandborn WJ; Schreiber S; Neimark E; Song A; Kligys K; Pang Y; Pivorunas V; Berg S; Duan WR; Huang B; Kalabic J; Liao X; Robinson A; Wallace K; D'Haens G Lancet; 2022 May; 399(10340):2031-2046. PubMed ID: 35644155 [TBL] [Abstract][Full Text] [Related]